Beigelman Leonid

CIK 00018247211 companySOUTH SAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001824721

Recent Transactions

23 trades

Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2023-03-15+169,500→ 169,500 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-07-07+113,000→ 113,000 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-02-04+56,700→ 56,700 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2022-02-04+226,800→ 226,800 total
Award
Aligos Therapeutics, Inc.$ALGS
Stock Option (Right to Buy)
2020-12-01+300,000→ 300,000 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+1,437→ 18,355 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-2 Preferred Stock
2020-10-20−21,724→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-2 Preferred Stock
2020-10-20−1,437→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+163,842→ 163,842 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+13,559→ 13,559 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+13,559→ 13,559 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+3,359→ 16,918 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+3,359→ 16,918 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series A Preferred Stock
2020-10-20−163,842→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+21,724→ 236,347 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+1,437→ 18,355 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series A Preferred Stock
2020-10-20−13,559→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-1 Preferred Stock
2020-10-20−50,781→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-1 Preferred Stock
2020-10-20−3,359→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series A Preferred Stock
2020-10-20−13,559→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-1 Preferred Stock
2020-10-20−3,359→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Series B-2 Preferred Stock
2020-10-20−1,437→ 0 total
Conversion
Aligos Therapeutics, Inc.$ALGS
Common Stock
2020-10-20+50,781→ 214,623 total

Companies

Aligos Therapeutics, Inc.
Director, President
$ALGS

Recent Filings

Address

C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR

SOUTH SAN FRANCISCO, CA, 94080

View on SEC.gov